Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Siemens Healthineers AG (SEMHF) and Johnson & Johnson (JNJ). Siem...

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and Johnson & Johnson (JNJ)

Exchange-traded funds (ETFs) remain a key way to capture growth opportunities in the market. Investors seeking exposure to industries such as tech,...

3 Best ETFs with 12%+, According to AI Analyst

Scotiabank analyst Louise Chen maintained a Buy rating on Johnson & Johnson today and set a price target of $305.00. According to TipRanks, Chen is...

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roivant Sciences (ROIV) and Johnson & Johnson (JNJ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

RBC Capital analyst Trung Huynh maintained a Buy rating on Johnson & Johnson on September 21 and set a price target of $287.00. The company’s share...

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TipRanks’ ETF AI Analyst has an Outperform rating on the Vanguard High Dividend Yield Index ETF ($VYM), Avantis U.S. Large Cap Value ETF ($AVLV), a...

3 ETFs That Could Deliver 10%+ Returns, According to the AI Analyst

TipRanks’ ETF AI Analyst has an Outperform rating on the State Street SPDR Portfolio S&P 500 ETF ($SPYM), Vanguard High Dividend Yield Index ETF ($...

These 3 ETFs Could Deliver Double-Digit Returns, Says the AI Analyst

In a report released today, Nico Chen from DBS maintained a Hold rating on Johnson & Johnson, with a price target of $270.00. According to TipRanks...

DBS Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

RBC Capital analyst Trung Huynh maintained a Buy rating on Johnson & Johnson on September 9 and set a price target of $287.00. The company’s shares...

RBC Capital Sticks to Its Buy Rating for Johnson & Johnson (JNJ)

RedHill Biopharma ($RHDL) has said the acquisition from Ferring of commercialization rights to two established gastrointestinal (GI) FDA-approved d...

RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio

TipRanks’ AI analyst rates Capital Group Dividend Value ETF ($CGDV), Invesco S&P 500 Momentum ETF ($SPMO), and JPMorgan Equity Premium Income ETF (...

3 ETFs with 12%+ Upside for Exposure to Tech, Industrials, and Healthcare, According to AI Analyst

Insiders have been trading these 5 stocks: (($NVDA)), (($TSM)), (($CRM)), (($CRWD)) and (($JNJ)). Here is a breakdown of their recent trades and th...

Nvidia, TSMC, Salesforce, CrowdStrike, J&J Insider Shake‑Up

TipRanks’ AI analyst rates Dimensional U.S. Equity ETF ($DFUS), Alerian MLP ETF ($AMLP), and Vanguard Value ETF ($VTV) as Outperform (Buy) for expo...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JNJ	$267.82	+0.09%	1.34M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JNJ	$267.82	+0.1%	1.34M
3
4
5
6

JNJ

Get Johnson & Johnson Data in Excel

Get Johnson & Johnson Data in Excel